Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$22.7M
63M shares
52-week range
$0.35 – $1.30
3% from low
Sector
SURGICAL & MEDICAL INSTRUMENTS & APPARATUS
Exchange
NASDAQ
CS
Borrow rate
0.81%
Easy to borrow
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $20.3M | $22.8M | $39.5M | $40.1M | $34.7M | $31.1M | $35.6M | $37.1M |
| Cost of revenue | $7.5M | $7.4M | $11.1M | $11.0M | $14.0M | $9.1M | $10.7M | $10.6M |
| Gross profit | $12.8M | $15.4M | $28.4M | $29.1M | $20.7M | $22.0M | $24.9M | $26.5M |
| Gross margin | 63.0% | 67.7% | 72.0% | 72.5% | 59.8% | 70.6% | 69.9% | 71.5% |
| R&D | $7.7M | $12.1M | $8.8M | $16.4M | $15.1M | $15.6M | $7.6M | $5.1M |
| Operating income | −$15.6M | −$19.0M | −$10.4M | −$22.7M | −$31.5M | −$31.9M | −$16.5M | −$14.2M |
| EBITDA | −$16.0M | −$18.7M | −$9.7M | −$24.2M | −$30.0M | −$27.9M | −$19.3M | −$4.4M |
| Net income | −$17.2M | −$19.3M | −$7.8M | −$24.6M | −$32.8M | −$29.2M | −$20.7M | −$8.2M |
| Net margin | -85.0% | -84.6% | -19.9% | -61.2% | -94.6% | -94.1% | -58.2% | -22.1% |
| EPS (diluted) | -0.56 | -0.60 | -0.20 | -0.57 | -0.75 | -0.65 | -0.38 | -0.13 |
Annual figures · source: Financial Modeling Prep
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $39M | $-0.17 | $-0.18–$-0.15 | 2 |
| 2027 | $47M | $0.03 | $0.03–$0.03 | 1 |
| 2028 | $52M | $0.06 | $0.06–$0.06 | 1 |
| 2029 | $54M | $0.08 | $0.08–$0.08 | 1 |
Forward consensus · source: Financial Modeling Prep
CytoSorbents Corp is a leader in blood purification for the treatment of life-threatening conditions in the intensive care unit and cardiac surgery. CytoSorbent's proprietary blood purification technologies are based on biocompatible, high-porous polymer beads that can actively remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption. CytoSorbent's technologies are used in several broad applications. Specifically, two important applications are: the removal of blood thinners during and after cardiothoracic surgery to reduce the risk of severe bleeding, and the removal of inflammatory agents and toxins in common critical illnesses that can cause massive inflammation, organ failure, and patient death. Geographically, in the USA, Germany, and Others.
www.cytosorbents.comNo one on the platform currently holds CTSO.
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 100,720 | $57.0K |
| Execution date | Ratio |
|---|---|
| 2014-12-05 | 1-for-25reverse |
| 2006-06-28 | 1-for-5.8reverse |
No one on the platform has traded CTSO yet.
| $12M |
| — |
| MDAISpectral AI, Inc. | $1.69 | -1.17% | $54M | — |
| NMTCNeuroOne Medical Technologies Corporation | $3.34 | +0.00% | $29M | — |
Source: Financial Modeling Prep · peers by sector/industry
Trading at 0.6× sales vs its 2.9× historical median P/S.
Fair value ≈ $1.90 · price $0.38 today
Fair-value line = the stock's median historical P/S × sales per share. Price below the orange line = cheap vs its own history; above = expensive. Not investment advice.
$CTSO They need to cancel the meeting and make a donation to the Trumps... if they want to succeed.
View on StockTwits ↗$CTSO presented at the Life Sciences Forum and said it scheduled two FDA meetings in August for its ticagrelor and DOAC programs.
View on StockTwits ↗$CTSO I still believe they will get FDA clearance in the near future.
View on StockTwits ↗CytoSorbents (NASDAQ: $CTSO ) brings its CytoSorb blood purification platform, with more than 300,000 devices sold across 70-plus countries, to the Life Sciences Virtual Investor Forum on June 24 at 11:30 AM ET. CytoSorbents Corporation (NASDAQ: CTSO) presents at the Life Sciences Virtual Investor Forum, co-hosted by Virtual Investor Conferences and Zacks Small Cap Research, at 11:30 AM ET on Wednesday, June 24, 2026, in a session moderated by Tom Kerr, CFA, Senior Analyst at Zacks Small Cap Research. The Life Sciences Virtual Investor Forum is a B2i Digital Featured Conference. For more details, please visit: https://b2idigital.com/vic-june-25th-life-sciences-virtual-investor-forum To register and view the presentation: https://www.virtualinvestorconferences.com/wcc/eh/4814904/lp/5397959/cytosorbents-corporation-nasdaq-ctso?utm_source=b2i&utm_medium=marketing&utm_campaign=0624LifeSciencesForumVIC Request a one-on-one meeting: https://app.axleaccess.com/public/events/636943bb-55cb-4a39-81b5-f658175de392?token=7b91921e-7b44-4da7-be93-ea5c37a5ed76 Phillip Chan, MD, PhD, CEO, presents for CytoSorbents alongside CFO Pete Mariani. Over the past 16 years Chan has led the company through EU approval and commercialization of its flagship CytoSorb product, and previously led healthcare and life science investments as a Partner at the NJTC Venture Fund. Mariani brings over 25 years as a strategic financial leader across high-growth medical technology companies, including CFO roles at Axogen and Hansen Medical. CytoSorbents is a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, with more than 300,000 CytoSorb devices sold across more than 70 countries to date. The company is seeking U.S. FDA market authorization for an investigational product, DrugSorb-ATR, designed to remove blood-thinning drugs. Learn more at https://ir.cytosorbents.com/. Virtual Investor Conferences is an OTC Markets Group Inc. property. Learn more at www.virtualinvestorconferences.com. Discover more emerging growth Featured Companies, industry-leading Featured Experts, and upcoming Featured Conferences at https://b2idigital.com. B2i Digital is the Official Marketing Partner of Virtual Investor Conferences. Content is informational only and is not investment advice. B2i Digital is not a broker-dealer or investment adviser.
View on StockTwits ↗$CTSO holds a Life Sciences Forum presentation on June 24 and investor meetings on June 30.
View on StockTwits ↗$CTSO wicks get filled Mr. Dunky “blues clues”
View on StockTwits ↗$CTSO CEO purchased 261,469 shares at $0.40 for a total of $104,898. Chan Phillip P. now owns 1,744,432 shares. https://ceo-buys.com
View on StockTwits ↗$CTSO Purchase by CEO: https://filingtracker.ai/filing/1175151/0001104659-26-074164
View on StockTwits ↗$CTSO preliminary proxy statement out. According to this preliminary proxy statement, existing shareholders can expect a reverse split anywhere from 1:5 to 1:20 at the discretion of the Board of Directors. I take no joy in being so right about this.
View on StockTwits ↗$CTSO spinout HemoDefend team with VC investment assistance and let Chan continue to underperform and continue to destroy shareholder value
View on StockTwits ↗$CTSO Reports 1st Quarter Financial and Operating Results https://buff.ly/MrIR4mC
View on StockTwits ↗$CTSO NEW ALL TIME LOW! SO SO SAD. WHY HASN’T THE BOARD ACTED???
View on StockTwits ↗Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.
Click to see transaction details on SEC.gov. Form 4s cover trades by officers, directors, and 10%+ owners, due within 2 business days of the trade.